Ascilion is a medical device company pioneering minimally invasive access to dermal interstitial fluid (dISF) to unlock a new generation of biomarker-driven diagnostics and monitoring. The company has developed a proprietary microneedle-based system designed to collect dISF in a simple, patient-friendly, and reproducible way, without the pain or complexity of traditional blood draws or skin biopsies. Because dISF reflects dynamic physiological processes at the tissue level, it offers rich insights into cosmetic efficacy, therapeutic response, and health status across a range of skin types. Ascilion’s platform is built to integrate seamlessly into clinical and research workflows, enabling high-quality sample collection suitable for advanced analytical methods. By making dISF accessible at scale, Ascilion aims to accelerate biomarker discovery, support precision medicine, and empower clinicians, researchers, and industry partners with more actionable biological data—bringing diagnostics closer to the biology that matters most.